Integra Lifesciences Holdings Stock News

Integra LifeSciences Holdings Co. (NASDAQ:IART) has earned an average rating of Hold from the ten ratings firms that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that have []

Exchange Traded Concepts LLC cut its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,309 shares of the life sciences companys stock after selling 8,020 shares during the quarter. Exchange Traded Concepts []

Exchange Traded Concepts LLC reduced its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,309 shares of the life sciences companys stock after selling 8,020 shares during the period. Exchange Traded []

The worldwide transcranial Doppler market can be fragmented into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. North American and European locales have huge geriatric populace. Hence, the rate of mental and cerebrum problems is higher in

Key Companies Covered in the Regenerative Medicine Market Research Report Are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and other key market players. Key Companies Covered in the Regenerative Medicine Market Research Report Are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and other key market players.

Parametric Portfolio Associates LLC lessened its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 17.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 172,056 shares of the life sciences companys stock after selling 36,356 shares during the []

Overview: Burn injuries are highly traumatic, extremely painful, and can lead to disfigurement, permanent scarring, or even death. The treatment of these injuries depends on the severity of burn, injured area, and depth of burn. Technologically advanced or modern burn care

Analysts expect Integra LifeSciences Holdings Co. (NASDAQ:IART) to post $0.84 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Integra LifeSciences earnings, with estimates ranging from $0.82 to $0.85. Integra LifeSciences also reported earnings per share of $0.84 during the same quarter last year. The []

The global Surgical Lamp market will grow at a CAGR of 2.54% from 2021 to 2027. Surgical Lamp are used in every dental surgery, hospital operation and procedure rooms, and ambulatory surgery centres. These lights are designed in a way

Metropolitan Life Insurance Co NY increased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 111,950.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 13,446 shares of the life sciences companys stock after acquiring an additional 13,434 shares during the period. Metropolitan []

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares got a boost as Q3 adjusted EPS of $0.86 topped the consensus forecast of $0.72. Revenues increased 4.5% Y/Y (6.7% organically) to $38

Integra LifeSciences' (IART) CEO Peter Arduini on Q3 2021 Results - Earnings Call Transcript

Integra (IART) delivered earnings and revenue surprises of 19.44% and 0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.